相关临床试验
86
46 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
2001
进行中（未招募）
46
53.5%
已完成
24
27.9%
No Longer Available
1
1.2%
招募中
6
7.0%
终止
6
7.0%
撤回
1
1.2%
- AVEO Oncology and HiberCell announced an exclusive development and option agreement for HC-5404, a first-in-human PERK inhibitor, to be combined with AVEO's approved VEGFR inhibitor FOTIVDA for renal cell carcinoma treatment. - Pre-clinical studies demonstrate HC-5404's enhanced anti-tumor efficacy when combined with anti-angiogenic agents in multiple solid tumor models including gastric cancer and RCC. - AVEO will conduct initial clinical development and has the option to obtain exclusive worldwide licensing rights during Phase 2 trials, with HiberCell eligible for milestone payments and royalties. - The collaboration leverages HC-5404's novel mechanism targeting the Unfolded Protein Response pathway, which cancer cells use to survive harsh tumor microenvironments.
- Over 90 pharmaceutical and biotech companies are actively developing more than 95 pipeline drugs for hepatocellular carcinoma (HCC). - Key companies like Can-Fite BioPharma are advancing HCC drug candidates, with some therapies in Phase III clinical trials. - Emerging therapies such as Namodenoson, SRF388, and Porustobart are expected to significantly impact the HCC market in the coming years. - The pipeline includes diverse routes of administration and molecule types, offering varied treatment options for HCC.
